Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is considered to benefit from chemotherapy. However, the significance of chemotherapy for those with lumin...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2014-07, Vol.14 (1), p.550-550, Article 550
Main Authors: Horimoto, Yoshiya, Arakawa, Atsushi, Tanabe, Masahiko, Sonoue, Hiroshi, Igari, Fumie, Senuma, Koji, Tokuda, Emi, Shimizu, Hideo, Kosaka, Taijiro, Saito, Mitsue
Format: Article
Language:English
Subjects:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer therapies
Chemotherapy
Endocrine therapy
Female
Gene amplification
Humans
Ki-67 Antigen - metabolism
Medical prognosis
Middle Aged
Neoadjuvant Therapy
Pathology
Patients
Receptor, ErbB-2 - metabolism
Statistical analysis
Surgery
Survival Analysis
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is considered to benefit from chemotherapy. However, the significance of chemotherapy for those with luminal tumours has decreased due to recent changes in treatment strategies. Thus, it is often difficult to determine whether we should recommend chemotherapy to such patients in clinical practice. We investigated Ki67 expression, as a means of predicting the responses of luminal HER2-negative breast cancer patients to neo-adjuvant chemotherapy (NAC), in order to identify a subpopulation that would benefit from these treatments. We enrolled 114 luminal HER2-negative breast cancer patients undergoing surgery after NAC. Biomarkers were examined using biopsy specimens obtained prior to treatment, to avoid any chemotherapy-related effects. Chemotherapy effects were determined employing operative specimens and we defined pathological complete response (pCR) as invasive nest disappearance, based only on the primary breast tumour. We applied receiver operating characteristic curve analysis to data from our 114 patients, to investigate Ki67 expression as a predictor of pCR. The pCR rate was significantly higher for tumours with high Ki67 expression (p 
ISSN:1471-2407
1471-2407
DOI:10.1186/1471-2407-14-550